Endophenotyping in alcoholic patients with glutamate spectoscopy: Genetic modulation and treatment response

Recruiting

• Conditions: F10.2

• Registration Number: DRKS00003350
• Lead Sponsor: Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-12-12
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

Men and women aged 18 to 65

- Legally effective, written informed consent for participation within the study

Alcohol dependent subjects:

- Diagnose of alcohol dependence according to ICD-10 and DSM-IV

Healthy controls:

- no or minimal consumption of alcohol,

- laboratory parameters sensitive for alcohol within normal range,

Exclusion Criteria

- Actual psychiatric disorder (Axis I) according to DSM-IV / ICD-10 (assessed with SCID-I) except nicotine abuse or nicotine dependence and alcohol dependence for patients
- Positive drugscreen (opiates, cannabinoids, benzodiazepines, barbiturates, cocaine, amphetamine),
- actual treatment with psychoactive medication,
- MR contraindication (e.g. pacemaker, metallic or electronic implants, metal splinters…)
- Severe physical disorders (liver-cirrhosis, severe diabetes),
- former psychotic disorder,
- actual suicidal tendency or endangerment of others

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
concentration of glutamate in the anterior cingulate cortex is assessed with MR-Spectroscopy at the beginning of acute alcohol withdrawal and after two weeks of abstinence

Secondary Outcome Measures

Name	Time	Method
genetic associations of glutamate concentration in the anterior cingulate cortex at the beginning of acute alcohol withdrawal and after two weeks of abstinence. Genes and genexpression are assessed via blood samples.